Cymabay Therapeutics Story Overview

CBAY -- USA Stock  

USD 12.41  0.005  0.0403%

Macroaxis does not monitor all media channels or aggregates social signals for Cymabay Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Cymabay Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Cymabay Therapeutics. Check also Cymabay Therapeutics Hype Analysis, Cymabay Therapeutics Correlation and Cymabay Therapeutics Performance.
Trading Sheet Reviewing the Levels for Cymabay Therapeutics, Inc.
Cymabay Therapeutics, Inc. presently has an EV or Enterprise Value of 291551. The EV helps show how the market assigns value to a company as a whole.

Read More...   

Story Momentum

This media report from www.concordregister.com distributed on December 7, 2017 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 0.73% . The overall trading delta when the story was published against the current closing price is 54.78% .

Similar stores for Cymabay Therapeutics

CymaBay Therapeutics Inc. Making Waves Price Change Triggers Interest From Investorsnews
The Coin GuildFull coverage
six days ago at http://cardinalweekly.com 
Hgk Asset Management Has Lowered By 774730 Its Applied Materials I Position Farallon Capital ...
news
The Cardinal Weekly This Small-Cap Semiconductor Stock Now Offers a Solid Dividend Motley FoolFull coverage
over a week ago at http://cardinalweekly.com 
Hightower Advisors Has Trimmed Its Idacorp Stake by 303336 as Stock Rose As Cymabay Share Price ...
news
The Cardinal Weekly Full coverage
over two weeks ago at http://thewellesleysnews.com 
CymaBay Therapeutics, Inc. Consensus EPS Outlook
news
Analyst JournalFull coverage
over two weeks ago at http://www.thecoinguild.com 
Stock Focus Investors Keen on Shares of CymaBay Therapeutics Inc. as it Makes Headlines With ...
news
The Coin GuildFull coverage
over three weeks ago at http://simplywall.st 
Breakeven On The Horizon For CymaBay Therapeutics Inc
news
Simply Wall StStock to Watch CymaBay Therapeutics Inc Alpha Beta StockWhat Everybody Ought to Know About These Marvell Technology Group Ltd. , Education Realty Trust ... The Stock Street CymaBay Therapeutics Added to the Russell 3000 and Russell 2000 Indexes NasdaqFull coverage
over a month ago at http://stocksmarketcap.com 
Hot Stocks Alert CymaBay Therapeutics Inc
news
Stocks Market CapFull coverage
over a month ago at http://www.thecoinguild.com 
Stock in the News Investors Taking a Second Look at CymaBay Therapeutics Inc.
news
The Coin GuildFull coverage
CymaBay Therapeutics, Inc. Stay Cool with Active Stocknews
News Stays On Track Full coverage
over a month ago at http://fintelegraph.com 
Investors need to watch this before making their mind up CymaBay Therapeutics, Inc. , Zayo Group Holdings ...
news
Financial TelegraphFull coverage
over a month ago at http://www.mmahotstuff.com 
Eam Investors Has Trimmed Its Cymabay Therapeutics Holding Valeant Pharmaceuticals International s ...
news
MoneyMakingArticlesWhat Are The Quant Signals Telling Us About CymaBay Therapeutics, Inc. The HeraldCymabay Share Price Rose While Abingworth Llp Has Cut Holding Segall Bryant Hamill Holding in Omnicell ... UtahHerald.comFull coverage
over three months ago at http://stocknewsgazette.com 
Financially Devastating or Fantastic SunPower Corporation , Cymabay Therapeutics, Inc.
news
StockNewsGazetteAs Cymabay Market Value Rose, Abingworth Llp Cut Its Position by 3.56 Million As Zoes Kitchen Holder Baldwin Brothers Upped Position Cymabay Therapeutics Holder Dafna Capital ... Bibeypost.comFull coverage
over three months ago at http://stocknewstimes.com 
CymaBay Therapeutics Upgraded by BidaskClub to Buy
news
CymaBay Therapeutics Inc logo BidaskClub upgraded shares of CymaBay Therapeutics from a hold rating to a buy rating in a report released on Friday, January 26th. Stocks with Perfect Investment Pair Cymabay Therapeutics, Inc. - NASDAQ Times It Seems Cymabay Therapeutics, Inc. Will Go Up. Have Another Big Increase - BZ Weekly

Total Debt

Total Debt Comparative Analysis
  Total Debt 
      Cymabay Therapeutics Comparables 
Cymabay Therapeutics is currently under evaluation in total debt category among related companies. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principle payments will eventually prevent the firm from borrow excessively.

Peers

Cymabay Therapeutics Related Equities
DNLI  4.01 %   
0%
100.0%
NK  3.95 %   
0%
98.0%
EDGE  2.00 %   
0%
49.0%
DRNA  1.36 %   
0%
33.0%
EARS  0.99 %   
0%
24.0%
DOVA  0.16 %   
0%
4.0%
DVAX  0.63 %   
15.0%
0%
ECYT  1.33 %   
33.0%
0%
DMPI  1.49 %   
37.0%
0%
CO  3.73 %   
93.0%
0%
Check also Cymabay Therapeutics Hype Analysis, Cymabay Therapeutics Correlation and Cymabay Therapeutics Performance. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">